Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIXC NASDAQ:BTMD NASDAQ:ENTX NASDAQ:HRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.01+2.2%$1.25$0.90▼$8.81$20.48M0.4974,264 shs19,939 shsBTMDbiote$2.26+3.0%$2.14$1.27▼$4.75$84.71M1.66252,691 shs35,502 shsENTXEntera Bio$1.78+9.8%$1.37$0.91▼$3.22$87.00M1.43592,689 shs182,775 shsHRTXHeron Therapeutics$0.42-1.6%$0.62$0.38▼$2.09$79.88M1.652.54 million shs2.26 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics+7.61%-4.79%-28.76%-20.15%+99,019,900.00%BTMDbiote-5.60%-2.67%-10.98%+11.17%-45.79%ENTXEntera Bio-1.22%-2.41%+31.71%+37.29%-10.00%HRTXHeron Therapeutics+3.12%+0.99%+7.45%-55.06%-79.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.01+2.2%$1.25$0.90▼$8.81$20.48M0.4974,264 shs19,939 shsBTMDbiote$2.26+3.0%$2.14$1.27▼$4.75$84.71M1.66252,691 shs35,502 shsENTXEntera Bio$1.78+9.8%$1.37$0.91▼$3.22$87.00M1.43592,689 shs182,775 shsHRTXHeron Therapeutics$0.42-1.6%$0.62$0.38▼$2.09$79.88M1.652.54 million shs2.26 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics+7.61%-4.79%-28.76%-20.15%+99,019,900.00%BTMDbiote-5.60%-2.67%-10.98%+11.17%-45.79%ENTXEntera Bio-1.22%-2.41%+31.71%+37.29%-10.00%HRTXHeron Therapeutics+3.12%+0.99%+7.45%-55.06%-79.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIXCQualigen Therapeutics 1.00SellN/AN/ABTMDbiote 2.50Moderate Buy$2.7521.95% UpsideENTXEntera Bio 2.00Hold$9.00405.90% UpsideHRTXHeron Therapeutics 2.00Hold$2.50491.02% UpsideCurrent Analyst Ratings BreakdownLatest AIXC, BTMD, HRTX, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/3/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.006/2/2026HRTXHeron Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/28/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/13/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/11/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/24/2026AIXCQualigen Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIXCQualigen TherapeuticsN/AN/AN/AN/A($0.75) per shareN/ABTMDbiote$192.22M0.44$0.56 per share4.00($1.40) per share-1.61ENTXEntera Bio$40K2,192.17N/AN/A$0.29 per share6.13HRTXHeron Therapeutics$154.90M0.52N/AN/A$0.07 per share6.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIXCQualigen Therapeutics-$16.97M-$6.47N/AN/AN/AN/A-771.52%-79.52%N/ABTMDbiote$27.05M$0.445.124.25N/A8.29%-25.72%15.12%8/5/2026 (Estimated)ENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-83.31%-70.83%8/14/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.18N/AN/AN/A-20.53%-7,747.30%-8.94%8/14/2026 (Estimated)Latest AIXC, BTMD, HRTX, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026BTMDbiote$0.07N/AN/AN/A$46.12 millionN/A5/12/2026Q1 2026AIXCQualigen TherapeuticsN/A-$0.79N/A-$0.79N/AN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/A5/6/2026Q1 2026BTMDbiote$0.09$0.06-$0.03$0.06$46.02 million$44.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIXCQualigen TherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIXCQualigen TherapeuticsN/A11.5711.57BTMDbioteN/A1.290.58ENTXEntera BioN/A7.937.93HRTXHeron Therapeutics17.512.531.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIXCQualigen Therapeutics3.18%BTMDbiote21.68%ENTXEntera Bio14.11%HRTXHeron Therapeutics80.01%Insider OwnershipCompanyInsider OwnershipAIXCQualigen Therapeutics1.17%BTMDbiote32.40%ENTXEntera Bio10.57%HRTXHeron Therapeutics6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIXCQualigen Therapeutics5020.24 million20.00 millionN/ABTMDbiote19437.58 million25.41 millionNot OptionableENTXEntera Bio2049.29 million44.08 millionOptionableHRTXHeron Therapeutics300189.28 million177.73 millionOptionableAIXC, BTMD, HRTX, and ENTX HeadlinesRecent News About These CompaniesNew Strong Sell Stocks for July 15thJuly 15 at 7:26 AM | zacks.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of "Hold" from BrokeragesJuly 12 at 6:13 PM | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Stock Passes Below Two Hundred Day Moving Average - Here's What HappenedJuly 8, 2026 | americanbankingnews.comIs Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?June 30, 2026 | finance.yahoo.comHeron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent DecisionJune 28, 2026 | finance.yahoo.comHeron Therapeutics (HRTX) Receives a Buy from H.C. WainwrightJune 9, 2026 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Heron Therapeutics (HRTX) and Praxis Precision Medicines (PRAX)June 6, 2026 | theglobeandmail.comHeron Therapeutics Appeals Ruling Invalidating CINVANTI PatentsJune 4, 2026 | theglobeandmail.comHeron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI PatentsJune 2, 2026 | finanznachrichten.deU.S. District Court Issues Decision Regarding CINVANTI® PatentsJune 2, 2026 | globenewswire.comWhy Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?May 19, 2026 | insidermonkey.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (ALXO) and Heron Therapeutics (HRTX)May 14, 2026 | theglobeandmail.comHeron Therapeutics (HRTX) price target decreased by 15.38% to 3.74May 14, 2026 | msn.comHeron (HRTX) Q1 2026 Earnings Call TranscriptMay 12, 2026 | finance.yahoo.comAcute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales DeclineMay 11, 2026 | finance.yahoo.comHeron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call TranscriptMay 11, 2026 | seekingalpha.comHeron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to SayMay 11, 2026 | zacks.comHeron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2026 | zacks.comHeron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms GuidanceMay 11, 2026 | globenewswire.comAnalysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out forMay 4, 2026 | zacks.comHeron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026April 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIXC, BTMD, HRTX, and ENTX Company DescriptionsQualigen Therapeutics NASDAQ:AIXC$1.01 +0.02 (+2.20%) As of 01:38 PM Eastern This is a fair market value price provided by Massive. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.biote NASDAQ:BTMD$2.26 +0.07 (+2.97%) As of 01:41 PM Eastern This is a fair market value price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Entera Bio NASDAQ:ENTX$1.78 +0.16 (+9.81%) As of 01:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Heron Therapeutics NASDAQ:HRTX$0.42 -0.01 (-1.61%) As of 01:41 PM Eastern This is a fair market value price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s AI Spending Question Looms Over Q2 Earnings 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger 3 Gold Stocks Under $5 With Massive Upside CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet Blueprint for a Billion: Nebius Group Secures the AI Floor Marriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
